- Home
- GNLX vs SKYE Comparison
GNLX vs SKYE Comparison
Compare GNLX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- SKYE
- Stock Information
- Founded
- GNLX 2001
- SKYE 2012
- Country
- GNLX United States
- SKYE United States
- Employees
- GNLX N/A
- SKYE N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- SKYE Health Care
- Exchange
- GNLX Nasdaq
- SKYE Nasdaq
- Market Cap
- GNLX 128.0M
- SKYE 121.8M
- IPO Year
- GNLX 2023
- SKYE N/A
- Fundamental
- Price
- GNLX $5.31
- SKYE $1.70
- Analyst Decision
- GNLX Strong Buy
- SKYE Strong Buy
- Analyst Count
- GNLX 4
- SKYE 5
- Target Price
- GNLX $17.75
- SKYE $14.75
- AVG Volume (30 Days)
- GNLX 134.5K
- SKYE 1.6M
- Earning Date
- GNLX 11-13-2025
- SKYE 11-06-2025
- Dividend Yield
- GNLX N/A
- SKYE N/A
- EPS Growth
- GNLX N/A
- SKYE N/A
- EPS
- GNLX N/A
- SKYE N/A
- Revenue
- GNLX N/A
- SKYE N/A
- Revenue This Year
- GNLX N/A
- SKYE N/A
- Revenue Next Year
- GNLX N/A
- SKYE N/A
- P/E Ratio
- GNLX N/A
- SKYE N/A
- Revenue Growth
- GNLX N/A
- SKYE N/A
- 52 Week Low
- GNLX $1.99
- SKYE $1.14
- 52 Week High
- GNLX $5.89
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- GNLX 79.41
- SKYE 29.59
- Support Level
- GNLX $4.17
- SKYE $1.78
- Resistance Level
- GNLX $4.83
- SKYE $4.99
- Average True Range (ATR)
- GNLX 0.29
- SKYE 0.34
- MACD
- GNLX 0.07
- SKYE -0.28
- Stochastic Oscillator
- GNLX 95.62
- SKYE 1.65
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.